Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 620-628

  Mazor, Y ^a,b   Almog, R ^a,b   Kopylov, U ^c   Ben Hur, D ^a   Blatt, A ^a   Dahan, A ^a   Waterman, M ^a,b   Ben Horin, S ^c   Chowers, Y ^a,b  

^a Gastroenterology Department   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; C REACTIVE PROTEIN; DRUG ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906236434     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12869     Document Type: Article

References (30)

1. Garces S, Demengeot J, Benito-Garcia E,. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2012; 72: 1947-55.
2. Sandborn WJ, Rutgeerts P, Enns R, et al,. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
5. Radstake TR, Svenson M, Eijsbouts AM, et al,. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-45.
6. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
7. Mok CC, van der Kleij D, Wolbink GJ,. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFalpha biologics in rheumatic diseases. Clin Rheumatol 2013; 32: 1429-35.
8. Karmiris K, Paintaud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
9. Vande Casteele N, Ballet V, Van Assche G, et al,. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012; 61: 321 author reply 2.
10. West RL, Zelinkova Z, Wolbink GJ, et al,. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-6.
11. Chiu YL, Rubin DT, Vermeire S, et al,. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013; 19: 1112-22.
12. Imaeda H, Takahashi K, Fujimoto T, et al,. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol 2014; 49: 100-9.
13. Wang SL, Hauenstein S, Ohrmund L, et al,. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal 2013; 78-79: 39-44.
14. Wolf DC, Scott H, Lockton S, Singh S,. Mechanisms of loss of response to adalimumab in Crohn's disease. Gastroenterology 2013; 144 (Suppl 1): s775.
15. Bodini G, Savarino V, Dulbecco P, et al,. Correlation between adalimumab trough serum concentration, anti-adalimumab antibodies and TNF-a levels with clinical outcome in patients affected by Crohn's disease [abstract]. Gastroenterology 2013; 144 (Suppl 1): s780.
16. Imaeda H, Takahashi K, Fujimoto T, et al,. Accurate determination of serum adalimumab and anti-adalimumab antibodies levels during maintenance therapy for Crohn's disease [abstract]. Gastroenterology 2013; 144 (Suppl 1): s431.
17. Velayos FS, Sheibani S, Lockton S, et al,. Prevalence of antibodies to adalimumab (ATA) and correlation between ata and low serum drug concentration on crp and clinical symptoms in a prospective sample of IBD patients [abstract]. Gastroenterology 2013; 144 (Suppl 1): s91.
18. Brandse JF, Wildenberg M, de Bruyn J, et al,. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease [abstract]. Gastroenterology 2013; 144 (Suppl. 1): s36.
19. Ordas I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87; quiz e85-6.
20. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
21. Ben-Horin S, Mazor Y, Yanai H, et al,. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35: 714-22.
22. Kopylov U, Mazor Y, Yavzori M, et al,. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18: 1628-33.
23. Billioud V, Sandborn WJ, Peyrin-Biroulet L,. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106: 674-84.
24. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68.
25. Liu X, Ye L, Bai Y, et al,. Activation of the JAK/STAT-1 signaling pathway by IFN-gamma can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG. J Immunol 2008; 181: 449-63.
26. Suzuki T, Ishii-Watabe A, Tada M, et al,. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184: 1968-76.
27. van der Valk ME, van Oijen MG, Ammerlaan M, et al,. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators. Gut 2012 Feb; 61: 324-5.
28. Reenaers C, Louis E, Belaiche J, et al,. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment Pharmacol Ther 2012; 36: 1040-8.
29. Colombel JF, Sandborn WJ, Reinisch W, et al,. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
30. Florin TH, Paterson EW, Fowler EV, et al,. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006; 41: 306-11.